A B S T R A C T The failure of certain adrenal tumors to respond to ACTH was investigated in vivo by administration of corticotropin-( 1-24) -tetracosapeptide (ACTH1-2) and dexamethasone and in vitro by studying the binding properties of ACTH1-2 and prostaglandin E1 (PGE1) and their effect on adenylate cyclase activity of the tumors' crude membranes; in addition, in five cases the stimulation of cortisol production in isolated adrenal cells by both hormones and dibutyryl cyclic adenosine 3',5'-monophosphate (cAMP) was also studied. The results obtained in 13 hormone-producing tumors of the human adrenal cortex, i.e. 10 carcinomas and 3 adenomas, were compared with those found in normal human adrenal glands.
INTRODUCTION
It is well known that in most of the human adrenocortical tumors ACTH does not stimulate steroidogenesis (1) . The biochemical anomaly responsible for this failure of stimulation of steroidogenesis by ACTH is still unknown. The same ACTH insensitivity has also been shown in vivo and in vitro for several types of adrenocortical tumors of the rat. In the tumor first described by Snell and Stewart (2) , the main biochemical abnormality seemed to be located beyond the formation of cyclic AMP (3) since neither ACTH nor cyclic AMP could increase steroidogenesis (4) (5) (6) 4 After Synacthen-Depot®, 1 mg/day for 2 days. § R., right; L., left.
cyclase activity in subcellular fractions was stimulated by ACTH (3) . In other mutant adrenal cell lines studied by Shimmer (7, 8) the anomaly was localized in the cell membrane since adenylate cyclase in adrenal subcellular preparations was not stimulated by ACTH, but cyclic AMP was still able to stimulate steroidogenesis. The purpose of this work was to establish whether in human adrenocortical tumors abnormalities of the ACTH receptors on the plasma membrane could be demonstrated. Therefore, we have studied the interaction of ACTH and also of prostaglandin E1 (PGE1)1 with subcellular fractions prepared from 13 tumors, and the results have been compared to those obtained with the same type of preparations from normal human adrenals.
METHODS
Materials. 13 human adrenocortical tumors were used for this study (10 carcinomas and 3 adenomas). The type and weight of the tumors as well as the output of 17-ketosteroids (17-KS) and 17-hydroxycorticosteroids (17- OHCS), measured by the method described by Few (9) 1 Abbreviations and trivial names used in this paper: ACTHSS o, corticotropin-(1-10)-decapeptide; ACTHlU", corticotropin-(1-24)-tetracosapeptide; ACTHEDu, corticotropin-(11-24) -tetradecapeptide; androstenedione, androst-4-ene-3, 17-dione; cortisol, 11,,17a,21-trihydroxypregn-4-ene-3,20-dione; DcAMP, dibutyryl cyclic adenosine 3',5'-monophosphate; dehydroepiandrosterone (DHA), 3fi-hydroxyandrost- (12) . This method was inapplicable to normal human adrenals be- Assay for ACTH degradation. The degradation of 'I-ACTH1-a was measured according to a method described previously (11) . Briefly, after incubation of "I-ACTH1, with the crude membrane preparation for 30 min at 40 C, the sample was layered over 2.5 ml of 20 mM Tris-HCl (pH 7.4) containing 0.25 M sucrose and 2% albumin and centrifuged at 50,000 g for 20 min at 0°C. Only the 1st ml of the supernate was aspirated and kept (unbound fraction). The pellet was washed once with 2 ml of the same buffer and centrifuged at 50,000 g for 20 min. The supernate was discarded and the pellet was resuspended in 0.5-1.0 ml of 1% acetic acid, shaken for 30 min at 220C, and centrifuged at 50,000 g for 10 min. The supernate (bound fraction) was removed and neutralized with 1 N NaOH. About 70-80%o of the radioactivity present in the pellet was recovered in the acetic acid fraction. The degradation of unbound and bound ACTH was measured by absorption of the labeled material on microfine silica (Quso G-32) and from its ability to bind to fresh adrenal crude membranes. The results were expressed as the percentage of the hormone that remains intact in relation to a control specimen that was incubated under the same conditions but without membranes.
Preparation of isolated cells. Isolated adrenal cells from normal adrenals and tumors were prepared according to a modification (15) (17) . Testosterone, androstenedione, and dehydroepiandrosterone (DHA) after separation and purification on Celite columns (Johns-Manville Products Corporation, New York) were measured by a sensitive radioimmunoassay (18) . The first steps of purification of DHA sulfate (DHAS) were performed as described (19) . After solvolysis, the compound was measured by radioimmunoassay as DHA.
Enzymatic activities. 5'-Nucleotidase was determined according to Heppel and Hilmor (20) , adenosine 3',5'-monophosphate phosphodiesterase was assayed by the method of Rutten, Schoot, and de Pont (21), and adenylate cyclase was measured as described elsewhere (13) . Protein content was estimated by the method of Lowry, Rosebrough, Farr, and Randall (22) with bovine serum albumin as standard.
RESULTS
In vivo effects of ACTH and dexamethasone administration. The urinary excretion of steroids after administration of ACTH or dexamethasone is shown in Table  I and the plasma content of steroids under the same conditions in patients where the test was available is shown in Table II . In addition, in patients 11 and 13 a perfusion of Synacthen® (Ciba Pharmaceutical Company, Summit, N. J.), 250 Ag in 500 ml of saline, was Cortisol production by isolated adrenal cells (Table  III) . Since the interpretation of the ACTH stimulation test in vivo was difficult, we decided, in the last five patients of our study (nos. 3, 6, 7, 9, and 10), to investigate the response of isolated adrenal cells to ACTH, PGE1, and DcAMP. Stimulation of cortisol production with ACTH was obtained in only one case (no. 3).
tumors of the virilizing type present a low secretion of cortisol, probably not submitted to the feed-back control mechanism which regulates the function of the normal adrenal. This could explain the responses to the tests in the patient 12, who, besides the adenoma, had an adrenal of normal macroscopic and microscopic aspect. This preparation also responded to DcAMP and PGE1. Namely, the stimulation obtained with 3 X 10-M ACTH was similar to that induced by 10' M DcAMP and higher than that due to 2 X 10' M PGE1. In the other four cases ACTH was unable to stimulate the cortisol production, but a stimulatory effect could be obtained by using DcAMP and PGE1 in three of the tumors (nos. 6, 7, and 9), while in tumor 10 only DcAMP increased slightly the cortisol production. Adenylate cyclase activity. The enzymatic activity of crude membranes under basal conditions varied from one tumor to another (Table IV) . With the exceptions of tumors 5, 9, and 13, it was generally lower than the activity found in the same preparation from normal human adrenals. Otherwise, the adenylate cyclase of the tumor preparations had similar characteristics to that from the normal adrenals. In the presence of a fixed concentration of ATP (0.53 mM), increasing amounts of Mg2' stimulated the enzyme and reached a plateau towards 4 mM. On the other hand, in the presence of a fixed concentration of Mg' (7.5 mM) the maximal enzymatic activity was obtained with 0.8-1 mM ATP. Further increase of the ATP concentration inhibited the adenylate cyclase activity. This inhibition was virtually complete at 3 mM ATP. Ca2" inhibited the enzyme and the inhibition was maximal at 10 mM.
Ethylene glycol bis(P-aminoethyl ether) NN'-tetraacetic acid (EGTA) and NaF stimulate the adenylate cyclase activity in crude membrane preparations of adrenal gland from several species (23) . In the normal human adrenal cortex the stimulation was maximal with concentrations of 0.1 mM EGTA and 6 mM NaF. At these concentrations, the stimulation was about 80 and 1,000% of the basal activity, respectively. In the tumor preparations the percent stimulation induced by EGTA was similar to that observed in normal adrenals, but the one induced by NaF was generally higher (Table  IV) .
PGE1 stimulates the adenylate cyclase activity in particulate preparations of human adrenals (13) . Maximal stimulation (100% of basal activity) is obtained with 5 X 10' M of the hormone. All tumors except no. 10 were sensitive to PGE1 (Table IV and Fig. 1) . However, the percentage of stimulation varied from one case to another. The stimulation was normal in cases 3-5, 9, and 13, low but significant in cases 1, 2, 6-8, 11, and 12, and undetectable in case 10 .
In crude membranes of normal human adrenals ACTH is able to induce a 100% stimulation of basal adenylate cyclase activity when used at a 10' M concentration; higher values lead to a reversal of the stimulation (Fig.  2) . Half-maximal stimulation is obtained with 6 X 10' M of ACTH.
In the tumors of our present investigation (Table IV ) the stimulation of adenylate cyclase activity induced by 10-5 M ACTH was unobtainable for seven cases (nos. 6-12), low but significant in three cases (nos. 1, 2, and 5) and normal in the last three cases (nos. 3, 4, and 13). The half-maximal stimulation was obtained with about 6 X 10' M ACTH. This value is calculated from experiments performed in tumors 3-5, where dose-response curves to increasing ACTH concentrations could be established (Fig. 2 ). An additive effect of ACTH and PGE1 on adenylate cyclase stimulation has been shown for normal ovine and human adrenals (Table IV and reference 3) . The same additive effect can be described for the tumors responsive to both hormones (nos. 1-5 and 13). Concentrations (10 M) of ACTH and PGE1 responsible for maximal stimulation of adenylate cyclase activity when added separately induce a further stimulatory effect when they are added simultaneously. In the tumors insensitive to ACTH, the PGE1 stimulation is not changed by the presence of ACTH, except in tumor 9, in which ACTH inhibits in part PGE1 stimulation.
Other hormones have been shown to be effective in stimulating the adenylate cyclase activity of the particulate fraction from the tumor 494 described by Snell and Stewart (2) . The tumors tested in the present study (nos. 2 and 8-10) did not respond to concentrations as high as 10' M of epinephrine, luteinizing hormone, glucagon, and insulin (data not shown).
The inability of ACTH1-s to stimulate the accumulation of cyclicAMP in tumors 6-12 could be attributed to one or several of the following abnormalities:
(a) Increase of the phosphodiesterase activity of the tumor crude membranes. This hypothesis is very unlikely since the stimulation of adenylate cyclase induced by other stimuli was normal or higher than normal and, when measured, the phosphodiesterase activity was lower than in normal adrenals (Table V) . These results are similar to those reported by Sharma (24) , who showed a lower phosphodiesterase activity in adrenal cortical tumors than in the normal adrenal in rats.
(b) Abnormal distribution of adenylate cyclase activity in subcellular fractions of adrenal tumors. The distributions of 5'-nucleotidase and adenylate cyclase in the different subcellular fractions of tumors (nos. 5 and 12) are given in Table VI and compared to results obtained in normal human adrenals. These two enzymatic activities were present in all of the particulate fractions in both tumors and the normal adrenal. The distribution of adenylate cyclase activity differed from the one observed in the normal adrenal (Table VI) (12) . (11) . This degradation is independent from the binding, and it only affects the ACTH that is not bound to its receptor. Preparations of crude membranes prepared from adrenal tumors also degraded unbound '"I-ACTH1-24 but did not degrade bound l"I-ACTHs-2X (Table VII) According to these criteria all the membranes prepared from the tumors specifically bound both labeled ACTH's. However, the apparent binding affinity of ACTH1-P for the tumors in which the adenylate cyclase was not stimulated by ACTH was about 10 times lower than that for normal adrenals and for tumors in which the adenylate cyclase was stimulated by ACTH. On the other hand, the binding affinity of ACTH11-24 was similar for both normal adrenals and all the tumors and about 10 times lower than the one of ACTH1-34 in a normal gland (Table VIII) In normal adrenal preparations ACTHi-io displaced bound 'I-ACTHi-n but not bound '"I-ACTHu-24 (14) . Owing to insufficient quantities of unlabeled ACTHi-io, we could study the effect of this peptide in only two cases. The results in Table IX show that ACTHi-io displaced bound 'I-ACTHi-24 in tumor 3 (ACTH responder) but did not in no. 6 (ACTH nonresponder) and suggest that the binding of the sequence 1-10 of ACTH may be specifically impaired in tumors 6-12. 
DISCUSSION
In the normal human adrenal ACTH is essential for the continuous production of glucocorticoids and an-drogens (25) . The first detectable step in the mechanism of action of ACTH is the binding of this hormone to specific adrenocortical receptors (26, 27) . This interaction is followed by a stimulation of the adenylate cyclase enzyme which is responsible for an increase in intracellular cyclic AMP level (28 (3) (4) (5) (6) whereas adenylate cyclase in particulate preparations was stimulated by the hormone (3) . Since in this tumor cyclic AMP did not stimulate steroidogenesis (4, 5) , it has been suggested (3) that the main anomaly responsible for the insensitivity to ACTH would occur after the formation of cyclic AMP. As our results suggest but do not confirm (since we could not test the effect of DcAMP on steroid production), the same anomaly could be present in some human adrenal cortical tumors. However, the similarity between human and rat tumors is far from complete. We have not found receptors for epinephrine and luteinizing hormone in the human tumors as were found in the rat tumor (30) . It also remains to be established if the multiple anomalies in the mechanism of action of ACTH on the rat tumor, described by Sharma (6, 31, 32) , are present in this group of human tumors.
The failure of ACTH to stimulate the cyclic AMP accumulation in our second group of tumors cannot be explained by an increased activity of the nucleotide phosphodiesterase (Table V) . Moreover, it is probably not due to an anomaly of the catalytic sites of adenylate cyclase, since the enzymatic activity was stimulated by PGE1, EGTA, and NaF. Therefore, the nonresponse to ACTH is probably related to a membrane anomaly. Adenylate cyclase insensitivities to specific hormones have already been reported for ACTH by Shimmer (8) in a mutant adrenal cell line and for thyroid-stimulating hormone by Macchia, Meldolesi, and Shiariello (33) in a rat thyroid tumor. In these cases, as in human adrenal tumors, the adenylate cyclase was stimulated by NaF.
The membrane anomaly in our second group of tumors could be located in the hormone binding receptor and/or at the level of the system coupling discriminator and catalytic sites. Although the binding of 'I-ACTH1-is specific in those tumors, the first hypothesis cannot be eliminated.
Recent studies concerning the relationship between the structure and the function of ACTH (12, 27, (34) (35) (36) (37) have shown that the peptide sequences necessary for the binding and for the biological action of this hormone are localized in two distinct parts of the molecule. The C-terminal (ACTH11i-) is important for binding (12) but has no biological action (37) whereas the N-terminal sequence (ACTH1-1o) has a very low binding affinity but is essential for biological action. In addition, it has been shown (11) clearly show that the binding affinity for ACTHl-24 is much lower than normal. It is similar to that for ACTHUn-n and not 10 times higher as in the normal gland or in the tumors sensitive to ACTH. This loss could not possibly be related to a modification of the site which binds the 11-24 sequence of the hormone since the binding affinity of the ACTHI-24 remained normal. Alternatively, the failure of ACTH1-1o to displace bound "I-ACTH1 2 in the tumor 6 strongly suggested that, at least in this example, the defect is probably due to a modification or a loss of the membrane component which normally binds the 1-10 sequence of ACTH. However, the possibility of an associated anomaly of the coupling system of the ACTH receptor cannot be ruled out by our study; nevertheless, this anomaly would not be extended to the coupling system of the PGE1 receptor since the hormone stimulated the adenylate cyclase activity of those tumors.
All the results presented so far for both tumors and normal adrenals can be reconciled in a diagram representing the receptors for ACTH and PGE1 such as the one proposed in Fig. 5 . Although no biological action has yet been described for ACTHn1-2, a possible role for the 11-24 sequence could be to increase the binding affinity of ACTH and therefore to allow the sequence 1-10 to fit in the second site. Only when this second site is occupied would the adenylate cyclase be stimulated. This model would also explain the case of the tumor (no. 10) of the last category which, in addition to the anomalies of the ACTH receptor, as for the second group, presents also an associated defect of the PGE1 receptor. The PGE, did not stimulate the adenylate cyclase of this preparation, and no significant binding could be observed with the tritiated hormone; however, it could not be demonstrated whether the defect consisted in a modification or a loss of the PGE,-binding site, which could or could not be associated with an anomaly of its coupling system.
It can be concluded from our study that in human adrenocortical tumors, a loss of sensitivity to ACTH can be related to a variety of biochemical abnormalities. They can affect different components of the ACTH receptor-adenylate cyclase complex or the message initiated by the formation of cyclicAMP. Further work in progress in this laboratory indicates that their detailed observation and analysis, despite an apparent heterogeneity, will give valuable information concerning the physiological role of the different peptide sequences of ACTH in the normal adrenal cell.
